Chebulinic Acid

CAS Number	18942-26-2 (live-verified; independent registry confirmation)
Molecular Formula / MW	C41H32O27 / ~956.7 g/mol
Chemical Class	Hydrolysable tannin (chebuloyl-type ellagitannin) — a galloylated glucose bearing a chebulic acid unit
Botanical Source	Terminalia chebula (haritaki; harad; black myrobalan) — also a Triphala constituent
Plant Part(s)	Fruit
Typical Standardisation	Chebulinic acid by HPLC; 5% commercial grade. Total tannins standardised separately
Claim Strength (Overview)	Emerging — broad preclinical pharmacology, but human clinical data on the isolated molecule is essentially absent
Buy from Herbuno	Chebulinic Acid 5% Powder (Haritaki Extract) | Standardized Terminalia chebula → Tannins 50% Powder (Haritaki Extract) | Standardized Terminalia Chebula →

Name origin: Chebulinic acid takes its name from Terminalia chebula, whose species epithet derives from Kabul — the Persian and Arabic trade route by which the fruit reached the West, giving it the old name "chebulic myrobalan." It is a hydrolysable tannin: a glucose core esterified with three galloyl groups and a chebuloyl unit. Its synonym eutannin appears in older literature. Traditional use: Terminalia chebula is haritaki, described in Ayurveda as one of the most important single drugs and sometimes styled the "king of medicines," used for digestion, constipation, respiratory complaints, and as a rasayana. It is one of the three fruits of Triphala, alongside T. bellirica and Emblica officinalis. Its therapeutic reputation was recognised well beyond India, entering Tibetan, Unani, and Chinese practice. Research trajectory: Approximately 149 compounds have been identified in the fruit, including tannins, phenolic acids, lignans, triterpenes, flavonoids, and volatiles. Chebulinic acid and chebulagic acid emerged as the two major bioactive hydrolysable tannoids, and modern research has pursued them across antioxidant, anti-inflammatory, antimicrobial, and antiproliferative endpoints — almost entirely in vitro and in animal models. Commercial source: Terminalia chebula fruit extract standardized to chebulinic acid content by HPLC.

---

Evidence for Chebulinic Acid Applications

Chebulinic acid is one of two dominant hydrolysable tannoids in Terminalia chebula, and the pair should be understood together. A comprehensive review of the fruit records that contemporary pharmacological research has demonstrated primarily antioxidant properties attributable to its rich phenolcarboxylic and tannic constituents — chebulagic acid, chebulinic acid, gallic acid, and ellagic acid — with chebulagic and chebulinic acid specifically recognised for substantial antioxidant capability, and the broader compound set showing antioxidant, anti-inflammatory, antiviral, anticancer, antibacterial, hepatoprotective, nephroprotective, neuroprotective, and antidiabetic activities (Molecules 2024). That breadth is genuine but should be read for what it is: a preclinical inventory, not a clinical dossier. Claim strength: Emerging.

The published review literature is candid about the gap, and it is worth repeating rather than glossing. A review of the traditional uses, bioactive constituents, and pharmacological activities of T. chebula fruits concludes explicitly that more in-vivo and clinical studies for mechanism-based pharmacological evaluation should be conducted to provide stronger scientific evidence for the traditional uses (Nigam 2020). A formulator should hold the position that the traditional record for haritaki is strong and the modern clinical record for isolated chebulinic acid is essentially absent — both statements are true simultaneously. Claim strength: Emerging.

The specific preclinical findings for chebulinic acid are reasonably well defined. It has demonstrated anti-secretory and cytoprotective effects on gastric ulcers, has been reported to elicit blood-pressure lowering in rats likely mediated by decreased cardiac output from reduced left ventricular contraction, and has been identified — alongside Triphala itself — as a natural inhibitor of VEGF-A-mediated angiogenesis. Growth-inhibitory activity against breast, osteosarcoma, and prostate cell lines has also been reported. These are specific, mechanistically distinct findings rather than generic antioxidant claims, which makes them more interesting and no more clinically established. Claim strength: Emerging.

The bioavailability question is the same one that governs the entire ellagitannin class, and it is the most important caveat on this page. Chebulinic acid is a large (~957 Da) polar hydrolysable tannin, and compounds of this class are not absorbed intact in meaningful quantity. As documented on the ellagitannin-related pages in this index, the systemically relevant molecules are typically the gut-microbiota-derived metabolites, not the parent tannin. Any claim premised on chebulinic acid reaching systemic circulation and acting on a distant tissue is making an assumption the pharmacokinetics do not support, and gut-local activity is the more defensible framing. Claim strength: High (established for the tannin class).

A compositional distinction that formulators regularly collapse: chebulinic acid and chebulagic acid are different molecules with different reported activity profiles — chebulagic acid, for instance, has shown potent anti-inflammatory effects in LPS-stimulated macrophages via NF-κB inhibition and has been studied for synergy with doxorubicin. They co-occur, they are both hydrolysable tannoids of T. chebula, and they are routinely conflated in marketing copy. A chebulinic-acid specification does not guarantee a chebulagic-acid content, and vice versa. Claim strength: High (compositional fact).

---

Dosage & Formulator Specification

Herbuno carries Terminalia chebula fruit extract standardized to 5% chebulinic acid by HPLC, alongside a 50% total-tannins haritaki grade, unstandardized haritaki extract powder, organic whole harad powder, and water-soluble and oil-soluble extracts. Buyers should note that a total-tannins figure and a chebulinic-acid figure are entirely different specifications and are not interchangeable.

No human dose-response data exists for isolated chebulinic acid, and any serving size presented as clinically validated for this molecule would be unsupported. Traditional haritaki dosing is at whole-fruit-powder scale (grams), which cannot be translated to a 5% standardized extract by simple arithmetic. Formulators should size against the assayed chebulinic acid content and should scope claims to the gut-local activity the pharmacokinetics support, or to the traditional whole-fruit record, rather than to systemic effects of the isolated tannin.

Analytical verification should specify chebulinic acid by HPLC against a certified reference standard, with chebulagic acid, gallic acid, and ellagic acid reported alongside — these co-occur and a single-marker figure conceals the rest of the tannin profile. Total tannins by a colorimetric method (Folin-Ciocalteu or similar) is a much cruder measure and should not be accepted as a substitute. Note that hydrolysable tannins degrade on exposure to heat, moisture, and alkaline pH, so extraction conditions and storage matter to the assayed profile.

Terminalia chebula has an extensive traditional and dietary safety record and is generally well tolerated. The principal cautions relate to its tannin content rather than to any specific toxicity. Hydrolysable tannins chelate iron and can meaningfully impair non-haem iron absorption, which is a real concern for populations with marginal iron status — a relevant consideration in the Indian market specifically — and separation from iron-containing meals or supplements is a reasonable precaution. Tannins may also bind and reduce the absorption of some oral medications and of dietary protein. Haritaki has a traditional laxative reputation, and gastrointestinal effects at higher intakes should be expected. Standard caution regarding use in pregnancy is appropriate.

---

Frequently Asked Questions — Chebulinic Acid

Is chebulinic acid absorbed into the bloodstream?
Not meaningfully — it is a large (~957 Da) polar hydrolysable tannin, and this class is not absorbed intact in significant quantity. The systemically relevant molecules from tannins are typically gut-microbiota-derived metabolites, not the parent compound. Claims premised on chebulinic acid reaching distant tissues are making an assumption the pharmacokinetics do not support.

Is chebulinic acid the same as chebulagic acid?
No, and they are routinely conflated. They are different molecules with different reported activity profiles — chebulagic acid, for instance, has shown potent NF-κB-mediated anti-inflammatory effects in macrophages. They co-occur in Terminalia chebula, but a chebulinic-acid specification does not guarantee a chebulagic-acid content.

How strong is the clinical evidence?
Thin, and the reviews say so. The pharmacology is broad and specific — gastric anti-secretory and cytoprotective effects, blood-pressure lowering in rats, VEGF-A-mediated angiogenesis inhibition — but it is essentially all preclinical. Review authors explicitly call for more in vivo and clinical studies. The traditional record for haritaki is strong; the modern clinical record for the isolated molecule is not.

Are there interaction concerns with chebulinic acid?
Mainly tannin-related. Hydrolysable tannins chelate iron and can meaningfully impair non-haem iron absorption — a real concern in populations with marginal iron status. They may also bind and reduce absorption of some oral medications and dietary protein. Separating intake from iron-containing meals or supplements is a reasonable precaution.

Related compounds: Tannins, Gallic Acid, Ellagic Acid, Corilagin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery